EMA Authorised: Sotyktu (deucravacitinib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Sotyktu (deucravacitinib) by Bristol-Myers Squibb Pharma EEIG for psoriasis in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 03/07/2024